PL377333A1 - Preparaty depot o kontrolowanym uwalnianiu - Google Patents

Preparaty depot o kontrolowanym uwalnianiu

Info

Publication number
PL377333A1
PL377333A1 PL377333A PL37733303A PL377333A1 PL 377333 A1 PL377333 A1 PL 377333A1 PL 377333 A PL377333 A PL 377333A PL 37733303 A PL37733303 A PL 37733303A PL 377333 A1 PL377333 A1 PL 377333A1
Authority
PL
Poland
Prior art keywords
controlled release
depot formulations
release depot
formulations
controlled
Prior art date
Application number
PL377333A
Other languages
English (en)
Polish (pl)
Inventor
Guohua Chen
Paul Houston
Roy Bannister
Teresa Kameda
David Priebe
Lothar Kleiner
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32312806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of PL377333A1 publication Critical patent/PL377333A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377333A 2002-11-06 2003-11-04 Preparaty depot o kontrolowanym uwalnianiu PL377333A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42442802P 2002-11-06 2002-11-06

Publications (1)

Publication Number Publication Date
PL377333A1 true PL377333A1 (pl) 2006-01-23

Family

ID=32312806

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377333A PL377333A1 (pl) 2002-11-06 2003-11-04 Preparaty depot o kontrolowanym uwalnianiu

Country Status (25)

Country Link
US (1) US7368126B2 (enExample)
EP (1) EP1581181B1 (enExample)
JP (1) JP2006508127A (enExample)
KR (1) KR20050088288A (enExample)
CN (1) CN1713890A (enExample)
AR (1) AR041913A1 (enExample)
AT (1) ATE418323T1 (enExample)
AU (1) AU2003295409B2 (enExample)
BR (1) BR0315304A (enExample)
CA (1) CA2504608C (enExample)
CL (1) CL2003002277A1 (enExample)
DE (1) DE60325511D1 (enExample)
EC (2) ECSP055838A (enExample)
MA (1) MA27523A1 (enExample)
MX (1) MXPA05004927A (enExample)
MY (1) MY140155A (enExample)
NO (1) NO20052635L (enExample)
NZ (1) NZ539810A (enExample)
PE (1) PE20040675A1 (enExample)
PL (1) PL377333A1 (enExample)
RU (1) RU2355385C2 (enExample)
TW (1) TW200503774A (enExample)
UY (1) UY28067A1 (enExample)
WO (1) WO2004043432A2 (enExample)
ZA (1) ZA200504529B (enExample)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
AU1375301A (en) * 1999-11-15 2001-05-30 Bio Syntech Canada Inc Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
DE60003459T2 (de) * 1999-12-09 2004-05-06 Biosyntech Canada Inc., Laval Mineral-polymer hybrid-zusammensetzung
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
DK1294414T3 (da) * 2000-06-29 2006-07-24 Biosyntech Canada Inc Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
EP1335687B1 (en) * 2000-11-15 2007-01-10 Bio Syntech Canada Inc. Method for restoring a damaged or degenerated intervertebral disc
US6699493B2 (en) * 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
AU2002359407B2 (en) * 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN1684663A (zh) 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
WO2004012703A1 (en) * 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
RU2005133427A (ru) * 2003-03-31 2006-04-27 Алза Корпорейшн (Us) Безводные однофазные носители и препараты с использованием таких носителей
JP2006521898A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 浸透送り出しシステム及び浸透送り出しシステムの始動時間を短縮する方法
US7207982B2 (en) * 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20050079202A1 (en) * 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
MX2007003968A (es) * 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
AR052155A1 (es) * 2004-12-14 2007-03-07 Novartis Ag Compuestos organicos
WO2006065951A2 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2006123360A2 (en) * 2005-03-01 2006-11-23 Sun Pharmaceutical Industries Limited Microspheres containing octreotide acetate
JP2009501200A (ja) * 2005-07-12 2009-01-15 レノボ・リミテッド ＴＧＦ−βスーパーファミリーメンバーを含有する医薬組成物
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007059605A1 (en) * 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
CN101869514B (zh) * 2005-11-16 2012-08-08 学校法人东海大学 用于治疗冠状动脉狭窄的支架
KR20130024988A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
US8236904B2 (en) 2005-12-28 2012-08-07 Ethicon, Inc. Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070149640A1 (en) * 2005-12-28 2007-06-28 Sasa Andjelic Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CN101677952B (zh) 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
WO2008149364A2 (en) * 2007-06-07 2008-12-11 Sarah Brenner Methods for diagnosing hypersensitivity reactions
US7923021B2 (en) * 2007-07-24 2011-04-12 University Of Memphis Research Foundation Local delivery method and composition
RU2343908C1 (ru) * 2007-09-05 2009-01-20 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и способ его применения
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US9090737B2 (en) * 2007-11-13 2015-07-28 Surmodics, Inc. Viscous terpolymers as drug delivery platform
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
CA2713339C (en) 2008-01-30 2017-01-17 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
EP3685837A1 (en) * 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
US9623222B2 (en) * 2008-10-30 2017-04-18 Warsaw Orthopedic, Inc. Drug depot with anchor
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2011031996A2 (en) * 2009-09-10 2011-03-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered microparticles for macromolecule delivery
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
US9993441B2 (en) 2009-12-30 2018-06-12 Surmodics, Inc. Controlled release matrix barrier structure for subcutaneous medical devices
KR102337046B1 (ko) 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
WO2011133370A1 (en) * 2010-04-23 2011-10-27 Medtronic, Inc. Shelf stable pharmaceutical depot
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US8492512B2 (en) * 2010-08-30 2013-07-23 Surmodics Pharmaceuticals, Inc. Process for reducing moisture in a biodegradable implant device
CA2810842C (en) * 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9597412B2 (en) 2011-03-16 2017-03-21 University Of Delaware Injectable delivery system for heparan-binding growth factors
CN102133180B (zh) * 2011-03-18 2016-03-09 黄芳 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法
US9005634B2 (en) 2011-04-13 2015-04-14 Medtronic, Inc. Shelf stable pharmaceutical depot
HUE066287T2 (hu) * 2011-04-25 2024-07-28 Geneora Pharma Shijiazhuang Co Ltd Nyújtott leadású mikroszféra risperidon készítmény
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
WO2013088255A1 (en) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
US9642697B2 (en) 2012-04-24 2017-05-09 Snu R&Db Foundation Breast prosthesis allowing controlled release of drug and production method for same
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
WO2014052518A1 (en) 2012-09-27 2014-04-03 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US9592227B2 (en) 2013-03-15 2017-03-14 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
EP4046628A1 (en) 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
BR112016012063B1 (pt) * 2013-12-31 2021-02-23 Pb&B Sa composição e usos da mesma
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160128997A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US20210228408A1 (en) 2015-07-23 2021-07-29 Allergan, Inc. Glaucoma Treatment Via Intracameral Ocular Implants
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CN109310680B (zh) 2016-06-30 2022-11-01 度瑞公司 长效配制物
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
WO2018227293A1 (en) 2017-06-13 2018-12-20 The University Of British Columbia Polymeric paste compositions for drug delivery
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN119185557A (zh) 2018-04-06 2024-12-27 阿玛治疗公司 用于控释治疗剂的组合物
CN109898236B (zh) * 2019-03-15 2021-12-14 深圳市光远生物材料有限责任公司 一种载药纳米纤维膜及其制备方法和应用
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN111548482B (zh) * 2020-04-02 2022-09-13 复旦大学 一氧化氮供体修饰的共聚物、包含其的缓释制剂及其制备方法与应用
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
CA3218153A1 (en) * 2021-06-30 2023-01-05 Soumya Rahima BENHABBOUR Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery
CN116270491A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种醋酸亮丙瑞林缓释微球及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797492A (en) 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3887790A (en) * 1974-10-07 1975-06-03 Vernon H Ferguson Wrap-around electric resistance heater
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5933320B2 (ja) * 1981-04-03 1984-08-15 株式会社東芝 光学的情報記録媒体
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4853218A (en) 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5085866A (en) 1988-12-02 1992-02-04 Southern Research Institute Method of producing zero-order controlled-released devices
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
GB9027422D0 (en) 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5288214A (en) 1991-09-30 1994-02-22 Toshio Fukuda Micropump
KR970007322B1 (ko) 1991-12-19 1997-05-07 미쓰이도오아쓰 가가쿠 가부시키가이샤 폴리히드록시 카르복실산 및 그 제조방법
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
US5468253A (en) 1993-01-21 1995-11-21 Ethicon, Inc. Elastomeric medical device
ATE212830T1 (de) 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
US5556905A (en) 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
UA10911C2 (uk) * 1994-08-10 1996-12-25 Мале Впроваджувальне Підприємство "Іhтерфалл" Біосумісhий гідрогель
US5639851A (en) 1995-10-02 1997-06-17 Ethicon, Inc. High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers
US6113624A (en) 1995-10-02 2000-09-05 Ethicon, Inc. Absorbable elastomeric polymer
ATE318580T1 (de) 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
JP2003501375A (ja) * 1999-06-04 2003-01-14 アルザ・コーポレーション 移植可能なゲル組成物および製造方法
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
WO2002038185A2 (en) * 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US20030152637A1 (en) 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
DE60231862D1 (de) * 2001-02-23 2009-05-20 Genentech Inc Erodierbare polymere zur injektion
NZ533434A (en) 2001-11-14 2006-11-30 Alza Corp Thixotropic gel composition for injectable deposition
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
AU2002359407B2 (en) * 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
TWI353854B (en) 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN1684663A (zh) 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
WO2004012703A1 (en) 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles

Also Published As

Publication number Publication date
ATE418323T1 (de) 2009-01-15
RU2005117164A (ru) 2006-01-20
CA2504608A1 (en) 2004-05-27
EP1581181A2 (en) 2005-10-05
US7368126B2 (en) 2008-05-06
ECSP055838A (es) 2005-09-20
CN1713890A (zh) 2005-12-28
ZA200504529B (en) 2006-08-30
CA2504608C (en) 2013-01-08
TW200503774A (en) 2005-02-01
MA27523A1 (fr) 2005-09-01
EP1581181B1 (en) 2008-12-24
BR0315304A (pt) 2005-08-16
NO20052635L (no) 2005-07-20
NO20052635D0 (no) 2005-06-01
MXPA05004927A (es) 2005-09-08
DE60325511D1 (de) 2009-02-05
UY28067A1 (es) 2003-12-31
MY140155A (en) 2009-11-30
JP2006508127A (ja) 2006-03-09
AU2003295409A1 (en) 2004-06-03
US20040151753A1 (en) 2004-08-05
AU2003295409B2 (en) 2010-02-11
RU2355385C2 (ru) 2009-05-20
NZ539810A (en) 2008-03-28
PE20040675A1 (es) 2004-09-25
HK1085387A1 (en) 2006-08-25
WO2004043432A2 (en) 2004-05-27
AR041913A1 (es) 2005-06-01
KR20050088288A (ko) 2005-09-05
ECSP056249A (es) 2006-10-17
CL2003002277A1 (es) 2005-05-06
WO2004043432A3 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
TWI347202B (en) Controlled release preparation
NO20052635D0 (no) Kontrollert frigivelsesdepot formuleringer
LT2279729T (lt) Kontroliuojamo atpalaidavimo preparatas
GB0218157D0 (en) Compositions for controlled release
IL162642A0 (en) Formulations
IL166424A0 (en) Sustained release formulations comprising lamotigine
GB0323701D0 (en) Formulations
GB0203421D0 (en) Composition
PL376840A1 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu
IL165865A0 (en) Short duration depot formulations
GB0203280D0 (en) Anti-glycolytic composition
GB0218194D0 (en) Solid formulations
GB0307765D0 (en) Tissue-adhesive formulations
TWI346555B (en) Vaccine composition
EP1495751A4 (en) hair dye
GB0214147D0 (en) Formulations
GB0211444D0 (en) Controlled release formulations
GB0215656D0 (en) Controlled release composition
GB0311354D0 (en) Controlled release formulations
GB0111389D0 (en) Controlled release formulations
GB0218567D0 (en) Formulations
GB0218037D0 (en) Vaccine composition
GB0203616D0 (en) Composition
TWI346556B (en) Vaccine composition
GB0322044D0 (en) Controlled release compositions

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)